Zobrazeno 1 - 10
of 80
pro vyhledávání: '"John L. Magnani"'
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
Neutrophils are essential to protect the host against invading pathogens but can promote disease progression in sickle cell disease (SCD) by becoming adherent to inflamed microvascular networks in peripheral tissue throughout the body. During the inf
Autor:
William E. Fogler, John L. Magnani, Michael Andreeff, Yannan Jia, Kyung Hee Chang, Lauren B Ostermann, Qi Zhang, Weiguo Zhang, Marina Konopleva, Mahesh Basyal
Publikováno v:
Blood. 138:1171-1171
FLT3 inhibitors (FLT3i) have had transient success treating FLT3-mutant acute myeloid leukemia (AML) patients, especially those with FLT3 internal tandem duplication (ITD) mutations that account for one-third of adult AML cases (Daver et al., 2021).
Autor:
William E. Fogler, John L. Magnani, Mateusz Rytelewski, Malgorzata Anna Zal, Rodrigo Jacamo, Kyung Hee Chang, Tomasz Zal, Michael Andreeff
Publikováno v:
Blood. 136:14-15
BACKGROUND: Acute myelogenous leukemia (AML) cells that reside in bone marrow (BM) receive a great deal of protection from the cytotoxic effects of therapeutic agents. In contrast, the circulating leukemia cells are typically more chemosensitive comp
Autor:
Lauren B Ostermann, Yannan Jia, M. Anna Zal, Weiguo Zhang, Mahesh Basyal, Michael Andreeff, Tomasz Zal, William E. Fogler, John L. Magnani, Kyung Hee Chang
Publikováno v:
Blood. 136:17-18
Acute myelogenous leukemia (AML) is characterized by an accumulation of abnormal white blood cells. Internal tandem duplications in the fms-like tyrosine kinase 3 (FLT3-ITD) account for 30% of adult AML cases and confer poor prognosis (Nakao et al.,
Autor:
Shaji Kumar, Elena Ellert, M. Andrulis, C. Connolly, W. E. Fogler, Lucy Kirkham-McCarthy, S. C. Locatelli-Hoops, Alessandro Natoni, Cian McEllistrim, I. Oliva, Niamh Keane, T. A.G. Smith, Michael O'Dwyer, Marc-Steffen Raab, Alokkumar Jha, Siobhan Glavey, John L. Magnani
Publikováno v:
Leukemia
Multiple myeloma (MM) is characterized by the clonal expansion and metastatic spread of malignant plasma cells to multiple sites in the bone marrow (BM). Recently, we implicated the sialyltransferase ST3Gal-6, an enzyme critical to the generation of
Autor:
Feda Azab, Justin King, Abdel Kareem Azab, Daniel Kohnen, Ravi Vij, Barbara Muz, William E. Fogler, John L. Magnani, Mark A. Fiala, Theodore A.G. Smith
Publikováno v:
Blood Cancer Journal
Blood Cancer Journal, Vol 9, Iss 9, Pp 1-6 (2019)
Blood Cancer Journal, Vol 9, Iss 9, Pp 1-6 (2019)
Autor:
Kyung Hee Chang, Weiguo Zhang, William E. Fogler, John L. Magnani, Mahesh Basyal, Michael Andreeff, Lauren B Ostermann
Publikováno v:
Clinical Lymphoma, Myeloma & Leukemia
Acute myeloid leukemia (AML) is an aggressive heterogeneous hematologic disease with high mortality in patients older than 60 years. Clinical studies have proven that combinations of FDA-approved Bcl-2 inhibitor, venetoclax and hypomethylating agents
Publikováno v:
Blood. 136:17-17
Background: In sickle cell disease (SCD), recurrent episodes of vaso-occlusive crisis (VOC) contribute to morbidity and accelerated mortality. Analysis of the RESET Phase 3 study demonstrated that administration of the pan-selectin inhibitor, rivipan
Autor:
John L. Magnani, Jean-Pierre Levesque, Joshua Tay, Ingrid G. Winkler, Corrine E Fiveash, Johanna D Erbani, Valerie Barbier
Publikováno v:
Blood. 134:2657-2657
We have previously shown vascular E (endothelial)-selectin to play a key role in niche-mediated chemo-resistance in Acute Myeloid Leukaemia (AML). Now we report that the cell surface glycosylation of AML blasts -and thus their E-selectin-binding pote
Autor:
William E. Fogler, Nalini Patel, William G. Rice, John L. Magnani, Weiguo Zhang, Gautam Borthakur, Sujan Piya, Mahesh Basyal, Hongying Zhang, Michael Andreeff
Publikováno v:
Blood. 134:3802-3802
Mantle cell lymphoma (MCL) is a rare subtype of aggressive B-cell non-Hodgkin lymphoma that remains incurable with standard therapy. Overexpression of B-cell receptor signaling through Bruton tyrosine kinase (BTK) is a hallmark of MCL (Pal Singh et a